TD Cowen analyst Charles Rhyee upgraded the rating on Icon to a Buy today, setting a price target of $120.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Charles Rhyee has given his Buy rating due to a combination of factors, starting with his view that the recent stock sell-off following Icon’s accounting investigation is disproportionate to the likely earnings impact. He estimates that the identified revenue overstatement will reduce sales by roughly 2% from 2026 onward, translating into about a mid-teens percentage hit to adjusted EPS, which is far smaller than the share price decline and creates an attractive entry point at a single-digit earnings multiple.
He also notes that cash generation remains solid, with Icon expected to produce around $1 billion of free cash flow over 2023–2025 and management indicating that cash balances are unaffected by the accounting issues. While acknowledging ongoing investigation risk and uncertainty around AI-related pressures, Rhyee believes the company’s current valuation, his revised earnings outlook, and a target multiple that embeds a meaningful risk discount together support a favorable risk-reward profile that justifies a Buy recommendation.
Rhyee covers the Healthcare sector, focusing on stocks such as Cardinal Health, Cigna, and CVS Health. According to TipRanks, Rhyee has an average return of 2.7% and a 50.20% success rate on recommended stocks.
In another report released on February 13, Robert W. Baird also maintained a Buy rating on the stock with a $119.00 price target.